 NEW YORK, Oct. 27, 2022 GLOBE NEWSWIRE -- Cellectis Euronext Growth: ALCLS - Nasdaq: CLLS, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter ended September 30th, 2022, on Thursday, November 3rd, 2022, after the close of the US market. 